Department of Vascular and Endovascular Surgery, Klinikum rechts der Isar-Technical University Munich, Biedersteiner Strasse 29, Munich, Germany.
Laboratory of Cardiovascular Pathology, Bristol Medical School, University of Bristol, Bristol, UK.
Cardiovasc Res. 2019 Oct 1;115(12):1732-1756. doi: 10.1093/cvr/cvz203.
Atherosclerosis underlies the predominant number of cardiovascular diseases and remains a leading cause of morbidity and mortality worldwide. The development, progression and formation of clinically relevant atherosclerotic plaques involves the interaction of distinct and over-lapping mechanisms which dictate the roles and actions of multiple resident and recruited cell types including endothelial cells, vascular smooth muscle cells, and monocyte/macrophages. The discovery of non-coding RNAs (ncRNAs) including microRNAs, long non-coding RNAs, and circular RNAs, and their identification as key mechanistic regulators of mRNA and protein expression has piqued interest in their potential contribution to atherosclerosis. Accruing evidence has revealed ncRNAs regulate pivotal cellular and molecular processes during all stages of atherosclerosis including cell invasion, growth, and survival; cellular uptake and efflux of lipids, expression and release of pro- and anti-inflammatory intermediaries, and proteolytic balance. The expression profile of ncRNAs within atherosclerotic lesions and the circulation have been determined with the aim of identifying individual or clusters of ncRNAs which may be viable therapeutic targets alongside deployment as biomarkers of atherosclerotic plaque progression. Consequently, numerous in vivo studies have been convened to determine the effects of moderating the function or expression of select ncRNAs in well-characterized animal models of atherosclerosis. Together, clinicopathological findings and studies in animal models have elucidated the multifaceted and frequently divergent effects ncRNAs impose both directly and indirectly on the formation and progression of atherosclerosis. From these findings' potential novel therapeutic targets and strategies have been discovered which may pave the way for further translational studies and possibly taken forward for clinical application.
动脉粥样硬化是大多数心血管疾病的基础,仍然是全球发病率和死亡率的主要原因。临床相关动脉粥样硬化斑块的形成、发展和形成涉及不同且重叠的机制的相互作用,这些机制决定了多种固有和募集的细胞类型的作用和功能,包括内皮细胞、血管平滑肌细胞和单核细胞/巨噬细胞。非编码 RNA(ncRNA)的发现,包括 microRNAs、长非编码 RNA 和环状 RNA,以及它们被鉴定为 mRNA 和蛋白质表达的关键机制调节剂,引起了人们对它们在动脉粥样硬化中的潜在贡献的兴趣。越来越多的证据表明,ncRNA 调节动脉粥样硬化所有阶段的关键细胞和分子过程,包括细胞侵袭、生长和存活;细胞摄取和流出脂质、表达和释放促炎和抗炎介质以及蛋白水解平衡。已经确定了动脉粥样硬化病变和循环中 ncRNA 的表达谱,目的是确定单独或簇 ncRNA 可能是可行的治疗靶点,并作为动脉粥样硬化斑块进展的生物标志物。因此,已经进行了许多体内研究,以确定调节选定的 ncRNA 的功能或表达在具有良好特征的动脉粥样硬化动物模型中的作用。综上所述,临床病理发现和动物模型研究阐明了 ncRNA 对动脉粥样硬化的形成和进展直接和间接产生的多方面且经常不同的影响。从这些发现中,已经发现了潜在的新的治疗靶点和策略,这可能为进一步的转化研究铺平道路,并可能进一步应用于临床。